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The angiotensin I-converting enzyme (ACE) is found in the
plasma membrane of vascular endothelial cells and on a variety of
extravascular tissues, while the soluble form of ACE circulates in
plasma. The inter-individual variability of human plasma and
cellular ACE levels is predominantly under the influence of a
genetic polymorphism in the ACE gene (Alhenc-Gelas et al,
1997), which corresponds to the presence or absence of a 287-bp
Alu-type sequence located in intron 16. Individuals homozygous
for the insertion (I genotype) have lower plasma and membrane-
bound ACE levels than those homozygotes without the insertion
(deletion, or D genotype), while heterozygotes display interme-
diate levels (DI geneotype) (Rigat et al, 1990). The DD genotype
is significantly associated with diabetic nephropathy in type I
diabetes (Marre et al, 1994), progressive renal dysfunction leading
to chronic renal failure in IgA nephropathy (Yoshida et al, 1995),
renal artery stenosis (Missouris et al, 1996) and end-stage renal
failure in polycystic kidney disease (Baboolal et al, 1997). We
considered whether the DD genotype occurs with an increased
frequency in patients developing renal cell carcinoma. We there-
fore analysed DNA derived from normal kidney tissue of 58
patients who underwent nephrectomy for primary renal tumours
for the prevalence of the I and D alleles, and for the incidence of
the DD genotype.
MATERIALS AND METHODS
Tissue specimens and PCR analysis
Surgically removed renal tumour specimens were obtained from
58 random patients undergoing radical nephrectomy at Memorial
Sloan-Kettering Cancer Center (MSKCC) and processed as
described (Nanus et al, 1990). Polymerase chain reaction (PCR)
was performed on DNA derived from the tumours using gene-
specific oligonucleotide primers as previously reported (Albino 
et al, 1991; Nanus et al, 1993a). A single PCR product of 190 bp
product was genotyped DD, of 490 bp product was genotyped II,
and if both 190 bp and 490 bp were present the sample was geno-
typed DI (Rigat et al, 1990). Any DNA sample genotyped DD
underwent a second amplification with a nested primer to confirm
the genotype (Shanmugan et al, 1993). Amplification of the ACE
gene used the following amplimers: sense 5¢-CTGGAGAC-
CACTCCCATCCTTTCT-3¢ and anti-sense 5¢-GATGTG-
GCCATCACATTCGTCAGAT-3¢ (Rigat et al, 1992). The DD
genotypes were confirmed using a nested sense primer 5¢-TTTGA-
GACGGAGTCTCGCTC-3¢ as described (Shanmugan et al,
1993). A c2 goodness of fit test was performed to determine if the
observed proportion match with the control proportion (Armitage
and Berry, 1987). Two-sided P-values are reported.
RESULTS
DNA was extracted from normal kidney obtained at nephrectomy
from 58 patients undergoing surgical resection of primary renal
tumours. There were of 36 males and 22 females with a median
age of 64 (range 32–83). Histological review revealed 46 clear cell
carcinomas and 12 non-clear cell histologies (four papillary 
carcinomas, four chromophobe carcinomas, four oncocytomas).
DNA was amplified using gene-specific primers for intron 16.
Representative PCR results are illustrated in Figure 1. The
frequency of the ACE D and I alleles for all 58 patients was 0.612
and 0.388 respectively. This frequency was similar to that
observed in a control population (Table 1). The observed frequen-
cies of 0.362, 0.50 and 0.138 for the DD, DI and II genotypes
respectively were not significantly different from the frequencies
predicted by Hardy–Weinberg equilibrium (c2 = 2.01; P = 0.4).
Subset analysis of the distribution of the D and I alleles in clear-
cell versus non-clear cell histology revealed a 75% incidence of
the D allele in patients with non-clear cell renal tumours (c2 = 3.7,
P = 0.06), however, there were only 12 samples in this cohort.
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The distribution of the ACE D and I alleles and the ACE geno-
types in 58 patients diagnosed with renal cell carcinoma was
similar to that observed in the normal population, and did not asso-
ciate with the development of renal cancer. These data contrast
multiple studies in which the DD polymorphism, which results in
elevated plasma and membrane bound ACE, is associated with the
development of benign renal diseases (Costerousse et al, 1997).
Elevated ACE levels lead to increased angiotensin II production
and bradykinin inactivation, and it is the increase in angiotensin II
that is believed to contribute to the numerous pathological states
associated with the DD genotype. Recent data indicate that
angiotensin II functions at the cellular level as a growth factor
(Wolf and Neilson, 1993; Wolf, 1995) and is essential for normal
growth and development of renal tubules (Alcorn and Maric,
1996).
Despite that the current study which did not identify an
increased frequency of the DD polymorphism does not implicate
elevated ACE and consequently increased angiotensin II levels in
the development of renal tumours, a number of recent studies do
suggest that the renin-angiotensin system plays a role in renal
carcinogenesis. Angiotensin II can induce the synthesis of basic
fibroblast growth factor (bFGF) (Itoh et al, 1993) which has been
implicated in the development and progression of renal cancers
(Nanus et al, 1993b). The ACE inhibitor Captopril significantly
reduces the tumour size of renal cancer xenografts in athymic mice
in a dose-dependent fashion (Hii et al, 1998). We have shown that
overexpression of aminopeptidase A, which converts angiotensin
II to angiotensin III, in renal cancer cells inhibits anchorage-
independent growth and tumorigenecity (unpublished data).
Finally, one recent study suggests that long-term use of ACE
inhibitors may protect against cancer (Lever et al, 1998). Taken
together, these data begin to implicate ACE and its substrates
including angiotensin II in the pathogenesis of renal cancers, and
indicate that the involvement of the tissue renin-angiotensin
system in this disease warrants further study.
In summary, the distribution of the ACE polymorphism in 58
patients with renal cell carcinomas is not significantly different
than the expected incidence in patients without renal cancers.
These data suggest that elevated ACE levels do not predispose to
the development of renal tumours. Further studies are needed to
define the involvement of the renin-angiotensin system in renal
carcinogenesis.
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Figure 1 PCR amplification of ACE alleles. Representative data of DNA
extracted from normal kidney tissue amplified using insertion-specific primers
for intron 16, and the PCR product separated on an agarose gel.
Representative samples shown: I genotype (lane 1); DI genotype (lanes 2
and 5); and DD genotype (lanes 3 and 4). MW = molecular weight marker
Table 1 Distribution of ACE alleles and genotypes in DNA of patients with
kidney cancer
CCa Non-CC All Controlsc
(n = 46) (n = 12) (n = 58) (n = 553)
ACE alleles
D 53 (0.576)b 18 (0.75) 71 (0.612) 0.555
I 39 (0.424) 6 (0.25) 45 (0.388) 0.445
ACE genotypes
DD 15 (0.341) 6 (0.5) 21 (0.362) 0.284
DI 23 (0.522) 6 (0.5) 29 (0.5) 0.533
II 8 (0.182) 0 8 (0.138) 0.183
aCC = clear cell carcinoma; Non-CC = non-clear cell. bNumber (fequency).
cOther population control as described (Schachter et al, 1994).552 BA Usmani et al
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